Xeropharmaceuticals Inc., a medical device maker, is seeking to capitalize on the soaring popularity of a new HIV treatment that combines an antiviral medication with a drug to treat anxiety.
The drug, called Xerofloxacin, or FLL, has been approved by the Food and Drug Administration in the U.S. and Europe and is being tested in Africa and Asia.
But the drugs, which can be prescribed for anxiety, depression and other conditions, are also being used to treat people who don’t have these problems.
It’s been an expensive treatment.
The drug costs about $100 a pill, according to data from the drug’s maker.
Xeropharma says its life insurance plan, called Life Insure, covers an annual deductible of up to $25 of the cost of Xeroplastim, or an antivirus drug.
Xermostom, the company’s insurance company, says it will cover a portion of the costs for the drug, and it will pay up to a third of the deductible and out-of-pocket costs, depending on how much is covered by Xermostum.
“The company is trying to capitalize and expand the use of this medication in people with a wide variety of mental health conditions, such as anxiety, chronic fatigue syndrome, PTSD, panic disorder, and anxiety disorder,” said Andrew Miller, CEO of Xermosom.
“Xeroflux has been shown to be a great treatment for these patients.”
The company also says it’s looking to expand its coverage to other conditions.
It said the company is offering life insurance coverage for people who want to use FLL to treat other conditions as well.
The insurance company’s website says the coverage is valid for coverage beginning July 1, 2019, for a maximum of one year, and can be renewed up to two years.
The company’s chief financial officer, Robert P. Wertheimer, said the new coverage is designed to increase the coverage available for people with severe mental illness.
Xerospin has been used in the treatment of other illnesses, such in post-traumatic stress disorder, depression, and schizophrenia, as well as in treatment of diabetes, epilepsy and asthma, he said.
“We believe that by working together with the FDA, we can continue to grow this important medication to the best possible benefit for our patients,” Wertheim said.
LifeInsure’s CEO, Robert A. Krieger, said that Xeroplosom is being used by more than 1 million people in the United States and Canada.
He said the drug is available in Canada for $75 a month.
“For our first-time customers, this is an excellent opportunity,” Krieberg said.
“Our goal is to increase our coverage in all regions of the world.”
Krieger said that the company has not yet found any insurance company that would cover the drug for less than $75.
He added that it could be more expensive to purchase life insurance, but the company said that would be a difficult proposition for a large company like LifeInsure to overcome.
“At this time, we are looking to work with insurance companies to provide insurance that covers the full cost of the drug,” Kieger said.
LifeInsurance said it expects to roll out Xeropoloxacins nationwide by the end of the year.
“Xeroplasts is a life-saving medication that has been proven effective for many mental health issues, including depression and anxiety,” said the LifeInsurancenetix website.
“We believe this medication is a perfect match for people seeking relief from the severe anxiety, panic and panic disorder that many people suffer from.”
“Our life insurance plans are focused on helping people with their health care needs, and are not designed to cover any additional expenses that are not covered by our insurance policies,” the company added.
The FDA said in a statement that Xermovast has been evaluated by the FDA to determine if it is safe and effective for people over the age of 18 and that it has received FDA clearance for its use.
The agency said that people in other countries can also use XermOVast to treat their own conditions, but that the drug has not been tested in people who have not been diagnosed with HIV.
“Because Xerovast is not approved in the US, we have not determined if it would be effective in other markets,” the agency said.